

**Biobanking Market by Product (Equipment, Consumables, Software), Services (Virtual), Operation (Automated), Workflow (Storage, Collection, Transport), Sample (Blood, Cell Lines, Nucleic Acids), Application, Ownership, End User - Global Forecast to 2030**

Market Report | 2025-08-23 | 492 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The biobanking market is projected to reach USD 11.82 billion by 2030 from USD 7.65 billion in 2025, at a CAGR of 9.1% during the forecast period. The growing focus on precision medicine and the expanding pipeline for cell and gene therapies are set to significantly fuel the growth of the biobanking market. Precision medicine, which tailors treatments to individual genetic profiles, is increasingly driving the need for high-quality, well-preserved biological samples, as these form the foundation for personalized therapies. Additionally, the growing pipeline for cell and gene therapies is expected to be a major driver for the biobanking market in the coming years. The development of new cell and gene therapies, which often rely on stem cells, gene editing, and other advanced biotechnologies, necessitates storing and managing vast amounts of biological material. Biobanks are essential in supporting these therapies by providing a reliable and standardized platform for sample storage, processing, and distribution.

<https://www.marketsandmarkets.com/Images/biobanking-devices-market-Overview.webp>

The physical biobanking segment accounted for the largest share of the biobanking services market in 2024. Based on services, the biobanking market is segmented into physical biobanking, virtual biobanking, and other services. In 2024, the large share of physical biobanking services in the market can be attributed to the essential role they play in sample collection, storage, and preservation under controlled conditions. Physical biobanks offer the infrastructure necessary to store a wide range of biological samples, including blood, tissues, and DNA, in environments such as freezers, cryogenic tanks, and refrigerators, ensuring sample integrity for long-term use. As the demand for high-quality biological specimens grows, driven by advancements

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

in precision medicine and genomics, physical biobanks are crucial for maintaining the stability and accessibility of these samples. Additionally, the ability to provide reliable, on-site sample management and real-time monitoring systems has further cemented the importance of physical biobanks in supporting pharmaceutical, biotechnology, and research sectors.

By ownership, the private/commercial providers segment accounted for the largest share of the market in 2024. Based on the ownership model, the biobanking services market is segmented into private/commercial providers, academic & research institutional biobanks, national/regional agencies, hybrid/PPP (public-private-partnership) models, and other ownership models. In 2024, the private/commercial providers segment accounted for the largest share of the global biobanking market. The large share of the private/commercial providers model in the biobanking market is primarily driven by the growing demand for high-quality, scalable, and commercially viable biobanking solutions. These providers can offer advanced, state-of-the-art infrastructure and technology for sample storage, processing, and distribution, often tailored to meet the specific needs of pharmaceutical, biotechnology, and clinical research sectors. Commercial providers are also more agile in adopting innovations and expanding their services to meet the evolving demands of precision medicine, genomic research, and clinical trials. Their ability to provide comprehensive, end-to-end biobanking services and focus on efficiency and regulatory compliance has made them essential partners for organizations seeking reliable and standardized biological sample management. As a result, the private/commercial ownership model continues to dominate the market, with private players capturing a significant share.

The US dominated the biobanking market in 2024.

In 2024, the US held a significant share of the North American biobanking market, driven by its advanced healthcare infrastructure, substantial investment in research and development, and leading role in precision medicine. With numerous world-renowned academic institutions, pharmaceutical companies, and research organizations, the US is at the forefront of generating and utilizing biological samples for a wide range of scientific advancements. The growing emphasis on personalized medicine, genomics, and clinical trials has increased the demand for high-quality biobanks in the region. Additionally, favorable regulatory frameworks and substantial public and private funding continue to support the expansion of biobanking services, solidifying the dominant position of the US in the market.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply-side- 70% and Demand-side 30%
- By Designation: Managers - 45%, CXOs & Directors - 30%, and Executives - 25%
- By Region: North America - 40%, Europe -25%, Asia Pacific -25%, Latin America -5% and the Middle East & Africa- 5%

List of Companies Profiled in the Report:

- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- PHC Holdings Corporation (Japan)
- Becton, Dickinson and Company (BD) (US)
- Qiagen (Germany)
- Merck KGaA (Germany)
- Labcorp (US)
- Eurofins Scientific (Luxembourg)
- Cryoport (US)
- ICON Plc (Ireland)
- Tecan Trading AG (Switzerland)
- Azenta US Inc. (US)
- Avantor, Inc. (US)
- Greiner AG (Austria)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Amsbio (UK)
- Labcorp (US)
- Eurofins Scientific (Luxembourg)
- Hamilton Company (US)
- BioIVT LLC (US)
- BioKryo (Germany)
- ASKION GmbH (Germany)
- Sopachem (Belgium)
- Froilabo (UK)
- Cureline (US)
- SPT Labtech Ltd (UK)

## Research Coverage

This research report categorizes the biobanking market by offerings [products (equipment, consumables), services (physical biobanking, virtual biobanking, other services), software]; workflow (sample collection & storage, sample processing, sample analysis, transport & logistics), operation type (manual, automated), sample type (blood products, solid tissues & organs, stem cell & cell lines, nucleic acids, biological fluids, human waste products), end user- product (biobanks, CROs), end -user services (pharma, biotech & CROs, academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa). The report's scope covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biobanking market. A thorough analysis of the key industry players has provided insights into their business overview, services, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, and acquisitions are the recent developments associated with the biobanking market.

## Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall biobanking market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (growing focus on precision medicine & population-genomics programmes, cell- & gene-therapy pipeline expansion, adoption of energy-efficient Ultra Low Temperature(ULT) freezers, end-to-end automation & robotics for physical sample handling and storage), restraints (high upfront capital expenditure, sample quality variability), opportunities ( outsourcing of cryogenic storage to third-party specialists, growing focus on sustainability and green-lab solutions), and challenges (long-term funding stability for public biobanks) influencing the growth of the market.
- Product/Service Development/Innovation: Detailed insights on newly launched products, services of the biobanking market
- Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions.
- Market Diversification: Exhaustive information about new products, services, untapped geographies, recent developments, and investments in the biobanking market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product & service offerings of key players including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (BD) (US), Qiagen (Germany), Labcorp (US), Eurofins Scientific (Luxembourg), Cryoport (US). A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, product launches, acquisitions, partnerships, agreements, collaborations, expansions, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the biobanking product and service market.

## Table of Contents:

1□INTRODUCTION□46

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1.1	STUDY OBJECTIVES	46
1.2	MARKET DEFINITION	46
1.3	STUDY SCOPE	46
1.3.1	BIOBANKING MARKET SEGMENTATION & REGIONAL SCOPE	47
1.3.2	INCLUSIONS & EXCLUSIONS	48
1.3.3	YEARS CONSIDERED	49
1.3.4	CURRENCY CONSIDERED	50
1.4	STAKEHOLDERS	50
1.5	SUMMARY OF CHANGES	50
2	RESEARCH METHODOLOGY	52
2.1	RESEARCH DATA	52
2.1.1	SECONDARY DATA	53
2.1.1.1	Key sources of secondary data	53
2.1.1.2	Key objectives of secondary research	53
2.1.2	PRIMARY DATA	54
2.1.2.1	Breakdown of primaries	54
2.1.2.2	Key objectives of primary research	55
2.2	MARKET ESTIMATION METHODOLOGY	55
2.2.1	GLOBAL MARKET SIZE ESTIMATION, 2024	55
2.2.1.1	Company revenue analysis (bottom-up approach)	55
2.2.1.2	MnM repository analysis	57
2.2.1.3	Primary interviews	58
2.2.1.4	Insights from primary sources	58
2.2.2	SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)	58
2.3	MARKET GROWTH RATE FORECAST	60
2.3.1	IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS	61
2.3.2	BIOBANKING MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS	62
2.4	DATA TRIANGULATION	62
2.5	STUDY ASSUMPTIONS	63
2.6	RESEARCH LIMITATIONS	64
2.7	RISK ANALYSIS	65
3	EXECUTIVE SUMMARY	66
3.1	KEY INSIGHTS & MARKET HIGHLIGHTS	66
3.2	STRATEGIC IMPERATIVES FOR STAKEHOLDERS	70
3.2.1	BIOBANKING EQUIPMENT MANUFACTURERS	70
3.2.2	BIOBANKING CONSUMABLE MANUFACTURERS	70
3.2.3	BIOBANKING SERVICE PROVIDERS	71
4	PREMIUM INSIGHTS	72
4.1	BIOBANKING MARKET OVERVIEW	72
4.2	NORTH AMERICA: BIOBANKING MARKET, BY OFFERING AND COUNTRY, 2024	73
4.3	BIOBANKING PRODUCTS MARKET SHARE, BY END USER, 2024	73
4.4	BIOBANKING SERVICES MARKET SHARE, BY END USER, 2024	74
4.5	BIOBANKING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	74
5	MARKET OVERVIEW	75
5.1	INTRODUCTION	75
5.2	MARKET DYNAMICS	75
5.2.1	DRIVERS	76

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.1.1	Growing focus on precision medicine & population genomics programs	76
5.2.1.2	Expansion of cell & gene therapy pipeline	77
5.2.1.3	Adoption of energy-efficient ULT freezers	77
5.2.1.4	Integration of end-to-end automation & robotics for sample handling & storage	78
5.2.2	RESTRAINTS	78
5.2.2.1	High capital expenditure	78
5.2.2.2	Variability associated with sample quality	79
5.2.3	OPPORTUNITIES	79
5.2.3.1	Outsourcing of activities by SME biopharma companies to third-party specialists	79
5.2.3.2	Increasing focus on sustainability & green-lab solutions	80
5.2.4	CHALLENGES	80
5.2.4.1	Challenges associated with long-term funding stability for public biobanks	80
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	81
5.3.1	STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES	81
5.4	PRICING ANALYSIS	82
5.4.1	AVERAGE SELLING PRICE OF BIOBANKING PRODUCTS, BY KEY PLAYER, 2024	82
5.4.2	INDICATIVE PRICING OF BIOBANKING SERVICES, BY SERVICE TYPE, 2024	83
5.4.3	INDICATIVE PRICING TREND FOR BIOBANKING MARKET, BY REGION, 2022?2024	83
5.5	VALUE CHAIN ANALYSIS	84
5.6	ECOSYSTEM ANALYSIS	85
5.6.1	ROLE IN ECOSYSTEM	86
5.6.2	EMERGING BUSINESS MODELS & ECOSYSTEM SHIFT IN BIOBANKING MARKET	88
5.7	PATENT ANALYSIS	88
5.8	LIST OF KEY PATENTS	90
5.9	TECHNOLOGY ANALYSIS	91
5.9.1	KEY TECHNOLOGIES	91
5.9.1.1	Automated sample collection and processing technologies	91
5.9.1.2	Sample analysis technologies	91
5.9.2	COMPLEMENTARY TECHNOLOGIES	92
5.9.2.1	Data management & informatics	92
5.9.2.2	AI & ML in biobanking	92
5.10	KEY CONFERENCES & EVENTS, 2025?2026	93
5.11	REGULATORY ANALYSIS	93
5.11.1	REGULATORY FRAMEWORK	94
5.11.1.1	North America	94
5.11.1.2	Europe	94
5.11.1.3	Asia Pacific	94
5.11.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	95
5.12	TRADE ANALYSIS	96
5.12.1	IMPORT DATA FOR HS CODE 8418, 2020-2024	96
5.12.2	EXPORT DATA FOR HS CODE 8418, 2020-2024	97
5.13	PORTER'S FIVE FORCES ANALYSIS	97
5.13.1	THREAT OF NEW ENTRANTS	98
5.13.2	THREAT OF SUBSTITUTES	99
5.13.3	BARGAINING POWER OF BUYERS	99
5.13.4	BARGAINING POWER OF SUPPLIERS	99
5.13.5	INTENSITY OF COMPETITIVE RIVALRY	99

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.14	KEY STAKEHOLDERS & BUYING CRITERIA	100
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	100
5.14.2	KEY BUYING CRITERIA FOR BIOBANKING PRODUCTS, BY END USER	101
5.14.3	KEY BUYING CRITERIA FOR BIOBANKING SERVICES, BY END USER	102
5.14.4	UNMET NEEDS & WHITE SPACES	103
5.15	INVESTMENT & FUNDING SCENARIO	104
5.15.1	VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE, 2024	105
5.16	IMPACT OF AI/GEN AI ON BIOBANKING MARKET	105
5.16.1	INTRODUCTION	105
5.16.2	USE CASES	105
5.16.3	FUTURE OF AI IN BIOBANKING MARKET ECOSYSTEM	106
5.17	IMPACT OF 2025 US TARIFF ON BIOBANKING MARKET	107
5.17.1	INTRODUCTION	107
5.17.2	KEY TARIFF RATES	107
5.17.3	PRICE IMPACT ANALYSIS	108
5.17.4	KEY IMPACTS ON COUNTRIES/REGIONS	108
5.17.4.1	North America	108
5.17.4.1.1	US	108
5.17.4.2	Europe	109
5.17.4.3	Asia Pacific	109
5.17.5	IMPACT ON END-USE INDUSTRIES	109
5.17.5.1	Biobanks	109
5.17.5.2	CROs	110
6	BIOBANKING MARKET, BY OFFERING	111
6.1	INTRODUCTION	112
6.2	PRODUCTS	113
6.2.1	EQUIPMENT	116
6.2.1.1	Freezers & refrigerators	118
6.2.1.1.1	Storage of blood, DNA, and serum to fuel market growth	118
6.2.1.2	Cryogenic storage systems	121
6.2.1.2.1	Rising demand for cell & gene therapies to fuel market	121
6.2.1.3	Alarm & monitoring systems	124
6.2.1.3.1	Regulatory demand for continuous monitoring to support market growth	124
6.2.1.4	Thawing equipment	126
6.2.1.4.1	Growing demand for CAR-T and mRNA therapies to fuel uptake	126
6.2.1.5	Temperature & humidity control systems	129
6.2.1.5.1	Critical role in maintaining sample integrity to aid adoption	129
6.2.1.6	Other equipment & accessories	132
6.2.2	CONSUMABLES	134
6.2.2.1	Surging sample volumes and recurring demand to drive market	134
6.3	SERVICES	137
6.3.1	OUTSOURCING OF SERVICES TO CROs TO DRIVE MARKET	137
6.4	SOFTWARE	140
6.4.1	GROWING FOCUS ON AUTOMATION TO PROPEL MARKET	140
7	BIOBANKING PRODUCTS MARKET FOR EQUIPMENT, BY OPERATION TYPE	144
7.1	INTRODUCTION	145
7.2	MANUAL OPERATIONS	145

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2.1 LARGE EXISTING INSTALLED BASE AND NO REQUIREMENT FOR SPECIALIZED LABOR TO DRIVE MARKET 145
- 7.3 AUTOMATED OPERATIONS 148
- 7.3.1 INCREASING INNOVATION AND RISING TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET 148
- 8 BIOBANKING PRODUCTS MARKET, BY WORKFLOW 152
- 8.1 INTRODUCTION 153
- 8.2 SAMPLE COLLECTION & STORAGE 153
- 8.2.1 LARGE RESEARCH COHORTS AND SUSTAINABILITY MANDATES TO DRIVE MARKET 153
- ?
- 8.3 SAMPLE PROCESSING 156
- 8.3.1 AUTOMATION DEMAND AND COMPLIANCE RULES TO FUEL MARKET 156
- 8.4 SAMPLE ANALYSIS 159
- 8.4.1 HIGH DEMAND FOR ACTIONABLE DATA TO FUEL MARKET 159
- 8.5 TRANSPORT & LOGISTICS 162
- 8.5.1 TEMPERATURE-SENSITIVE REQUIREMENTS TO SUPPORT PRODUCTS UPTAKE 162
- 9 BIOBANKING PRODUCTS MARKET, BY SAMPLE TYPE 166
- 9.1 INTRODUCTION 167
- 9.2 BLOOD PRODUCTS 167
- 9.2.1 EASE OF COLLECTION AND ANALYTICAL VERSATILITY TO PROPEL MARKET 167
- 9.3 SOLID TISSUES & ORGANS 170
- 9.3.1 GROWTH IN SPATIAL OMICS TO FUEL MARKET 170
- 9.4 STEM CELLS & CELL LINES 173
- 9.4.1 ADOPTION OF REGENERATIVE MEDICINE TO BOOST DEMAND 173
- 9.5 BIOLOGICAL FLUIDS 175
- 9.5.1 UTILIZATION FOR DISEASE-MECHANISM STUDIES TO FUEL UPTAKE 175
- 9.6 NUCLEIC ACIDS 178
- 9.6.1 INTEGRATION OF MULTI-OMICS TO BOOST DEMAND 178
- 9.7 HUMAN WASTE PRODUCTS 181
- 9.7.1 APPLICATIONS ACROSS MICROBIOME RESEARCH TO FUEL UPTAKE 181
- 10 BIOBANKING PRODUCTS MARKET, BY END USER 184
- 10.1 INTRODUCTION 185
- 10.2 BIOBANKS 185
- 10.2.1 GROWING FOCUS ON LIFE SCIENCES & CLINICAL RESEARCH TO BOOST DEMAND 185
- 10.3 CROSS 188
- 10.3.1 GROWING FOCUS ON BIOMARKER TRIALS AND OUTSOURCING OF SERVICES TO SUPPORT MARKET 188
- 11 BIOBANKING SERVICES MARKET, BY OWNERSHIP 192
- 11.1 INTRODUCTION 193
- 11.2 PRIVATE/COMMERCIAL BIOBANKS 193
- 11.2.1 TECHNOLOGICALLY ADVANCED INFRASTRUCTURE AND COMPLIANCE OFFERINGS TO PROPEL MARKET 193
- 11.3 ACADEMIC & RESEARCH INSTITUTION BIOBANKS 196
- 11.3.1 FAVORABLE FUNDING ACTIVITIES TO BOOST DEMAND 196
- 11.4 NATIONAL/REGIONAL AGENCIES 199
- 11.4.1 GOVERNMENT FOCUS ON ADVANCING HEALTHCARE RESEARCH INITIATIVES TO DRIVE MARKET 199
- 11.5 HYBRID/PPP MODELS 202
- 11.5.1 HIGH CREDIBILITY AND AGILITY TO SUPPORT MARKET GROWTH 202
- 11.6 OTHER OWNERSHIP MODELS 205
- 12 BIOBANKING MARKET, BY APPLICATION 208
- 12.1 INTRODUCTION 209

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2 RESEARCH APPLICATIONS 209
  - 12.2.1 LIFE SCIENCE RESEARCH 212
    - 12.2.1.1 Increasing focus on genomics projects to fuel uptake 212
  - 12.2.2 CLINICAL RESEARCH 215
    - 12.2.2.1 Growing regulatory requirements and decentralized & hybrid trials to support market growth 215
- 12.3 THERAPEUTIC APPLICATIONS 218
  - 12.3.1 GROWING DEMAND FOR CELL & GENE THERAPIES TO PROPEL MARKET 218
- 12.4 DIAGNOSTIC APPLICATIONS 220
  - 12.4.1 REQUIREMENT OF DISEASE-SPECIFIC SAMPLES TO BOOST DEMAND 220
- 12.5 OTHER APPLICATIONS 223
- 13 BIOBANKING SERVICES MARKET, BY TYPE 226
  - 13.1 INTRODUCTION 227
  - 13.2 PHYSICAL BIOBANKING SERVICES 227
    - 13.2.1 MEGA-COHORTS IN ONCOLOGY & POPULATION GENOMICS TO PROPEL MARKET 227
  - 13.3 VIRTUAL BIOBANKING 230
    - 13.3.1 EASE OF SPECIMEN ACCESS FOR END USERS TO DRIVE MARKET 230
  - 13.4 OTHER SERVICES 233
- 14 BIOBANKING SERVICES MARKET, BY END USER 236
  - 14.1 INTRODUCTION 237
  - 14.2 PHARMA-BIOTECH COMPANIES & CROS 237
    - 14.2.1 EXPANDING DRUG DISCOVERY & DEVELOPMENT PIPELINE TO PROPEL MARKET 237
  - 14.3 ACADEMIC & RESEARCH INSTITUTES 240
    - 14.3.1 ADVANCEMENTS IN RESEARCH AND FAVORABLE GRANTS TO BOOST DEMAND 240
  - 14.4 HOSPITALS & DIAGNOSTIC LABORATORIES 243
    - 14.4.1 USE OF SAMPLES FOR THERAPEUTIC & DIAGNOSTIC PURPOSES TO AID MARKET 243
- 15 BIOBANKING MARKET, BY REGION 246
  - 15.1 INTRODUCTION 247
  - 15.2 NORTH AMERICA 247
    - 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 253
      - 15.2.2 US 254
        - 15.2.2.1 US to dominate North American biobanking market during forecast period 254
      - 15.2.3 CANADA 258
        - 15.2.3.1 Strong public investment with national research networks and collaborations to support disease-focused biobanking 258
    - 15.2.2.2 US to dominate North American biobanking market during forecast period 254
    - 15.2.3 CANADA 258
      - 15.2.3.1 Strong public investment with national research networks and collaborations to support disease-focused biobanking 258
  - 15.3 EUROPE 262
    - 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 267
      - 15.3.2 GERMANY 268
        - 15.3.2.1 High government funding and focus on advanced clinical research to augment market growth 268
      - 15.3.3 UK 273
        - 15.3.3.1 Presence of large-scale, population-based advanced research infrastructure to propel market growth 273
      - 15.3.4 FRANCE 277
        - 15.3.4.1 Growing focus on quality standards, open science, and international collaboration to support market growth 277
      - 15.3.5 ITALY 281
        - 15.3.5.1 Improved healthcare standards to support biobanking studies in cancer, rare diseases, and personalized medicine healthcare 281
      - 15.3.6 SPAIN 286
        - 15.3.6.1 Adoption of international standards and advanced government-backed infrastructure to aid market growth 286
      - 15.3.7 REST OF EUROPE 290

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.4	ASIA PACIFIC	294
15.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	300
15.4.2	CHINA	301
15.4.2.1	Increased research collaborations and advancements in biobank infrastructure to drive market	301
15.4.3	JAPAN	305
15.4.3.1	Strong genomic research output and focus on AI-driven polygenic risk scoring to boost predictive healthcare innovation	305
15.4.4	INDIA	309
15.4.4.1	National and disease-specific initiatives for advanced precision medicine and healthcare innovation to aid market growth	309
15.4.5	AUSTRALIA	314
15.4.5.1	Increasing national investments in disease-specific, microbiome, and wildlife biobanks to accelerate market growth	314
15.4.6	SOUTH KOREA	318
15.4.6.1	Increased quality standards and more international collaborations to support human and environmental biobanking	318
15.4.7	REST OF ASIA PACIFIC	323
15.5	LATIN AMERICA	327
15.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	332
15.5.2	BRAZIL	333
15.5.2.1	Genetic diversity and large-scale stem cell & genomic initiatives to propel market growth	333
15.5.3	MEXICO	337
15.5.3.1	Favorable initiatives for improving population health research and representation in global genomic databases to drive market	337
15.5.4	REST OF LATIN AMERICA	341
15.6	MIDDLE EAST	346
15.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST	351
15.6.2	GCC COUNTRIES	352
15.6.2.1	Kingdom of Saudi Arabia (KSA)	357
15.6.2.1.1	Investments in automated equipment biobank infrastructure, ISO accreditation, and Vision 2030 to boost market growth	357
15.6.2.2	UAE	361
15.6.2.2.1	Investments in AI-driven robotic biobanking to fuel market growth	361
15.6.2.3	Rest of GCC countries	365
15.6.3	REST OF MIDDLE EAST	371
15.7	AFRICA	376
15.7.1	GROWING STANDARDIZATION EFFORTS, INTERNATIONAL ACCREDITATION, AND CAPACITY-BUILDING TO PROPEL MARKET GROWTH	376
15.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	380
16	COMPETITIVE LANDSCAPE	382
16.1	INTRODUCTION	382
16.2	KEY PLAYERS STRATEGIES/RIGHT TO WIN	382
16.3	REVENUE ANALYSIS, 2020-2024	384
16.3.1	REVENUE ANALYSIS FOR BIOBANKING PRODUCTS, 2020-2024	384
16.3.2	REVENUE ANALYSIS FOR BIOBANKING SERVICES & SOFTWARE, 2020-2024	386
16.4	MARKET SHARE ANALYSIS, 2024	386
16.4.1	MARKET SHARE ANALYSIS FOR BIOBANKING PRODUCTS, 2024	386
16.4.2	MARKET SHARE ANALYSIS FOR BIOBANKING SERVICES & SOFTWARE, 2024	388
16.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	390

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.5.1	STARS	391
16.5.2	EMERGING LEADERS	391
16.5.3	PERVASIVE PLAYERS	391
16.5.4	PARTICIPANTS	391
16.5.5	COMPANY FOOTPRINT, KEY PLAYERS, 2024	393
16.5.5.1	Company footprint	393
16.5.5.2	Region footprint	394
16.5.5.3	Offering footprint	395
16.5.5.4	Sample type footprint	396
16.5.5.5	Workflow footprint	397
16.6	COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024	397
16.6.1	PROGRESSIVE COMPANIES	397
16.6.2	RESPONSIVE COMPANIES	397
16.6.3	DYNAMIC COMPANIES	398
16.6.4	STARTING BLOCKS	398
16.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	399
16.6.5.1	Detailed list of key startups/SMEs	399
16.6.5.2	Competitive benchmarking of startups/ SMEs	400
16.7	COMPANY VALUATION & FINANCIAL METRICS	401
16.7.1	COMPANY VALUATION & FINANCIAL METRICS FOR BIOBANKING PRODUCTS MARKET	401
16.7.1.1	Company valuation	401
16.7.1.2	Financial metrics	401
16.7.2	COMPANY VALUATION & FINANCIAL METRICS FOR BIOBANKING SERVICES & SOFTWARE MARKET	402
16.7.2.1	Company valuation	402
16.7.2.2	Financial metrics	402
16.8	BRAND/PRODUCT COMPARATIVE ANALYSIS	403
16.9	COMPETITIVE SCENARIO	404
16.9.1	PRODUCT/SERVICE/SOLUTION LAUNCHES	404
16.9.2	DEALS	405
16.9.3	EXPANSIONS	406
17	COMPANY PROFILES	407
17.1	KEY PLAYERS	407
17.1.1	THERMO FISHER SCIENTIFIC INC.	407
17.1.1.1	Business overview	407
17.1.1.2	Products/Services/Solutions offered	408
17.1.1.3	Recent developments	414
17.1.1.3.1	Product launches	414
17.1.1.3.2	Deals	415
17.1.1.3.3	Expansions	415
17.1.1.4	MnM view	416
17.1.1.4.1	Key strengths	416
17.1.1.4.2	Strategic choices	416
17.1.1.4.3	Weaknesses & competitive threats	416
17.1.2	PHC HOLDINGS CORPORATION	417
17.1.2.1	Business overview	417
17.1.2.2	Products/Services/Solutions offered	418
17.1.2.3	Recent developments	420

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.1.2.3.1□Product launches□420
- 17.1.2.4□MnM view□421
  - 17.1.2.4.1□Key strengths□421
  - 17.1.2.4.2□Strategic choices□421
  - 17.1.2.4.3□Weaknesses & competitive threats□421
- ?
- 17.1.3□BECTON, DICKINSON AND COMPANY (BD)□422
  - 17.1.3.1□Business overview□422
  - 17.1.3.2□Products/Services/Solutions offered□423
  - 17.1.3.3□Recent developments□425
    - 17.1.3.3.1□Product launches□425
    - 17.1.3.4□MnM view□426
      - 17.1.3.4.1□Key strengths□426
      - 17.1.3.4.2□Strategic choices□426
      - 17.1.3.4.3□Weaknesses & competitive threats□426
- 17.1.4□QIAGEN□427
  - 17.1.4.1□Business overview□427
  - 17.1.4.2□Products/Services/Solutions offered□428
  - 17.1.4.3□Recent developments□431
    - 17.1.4.3.1□Product launches□431
    - 17.1.4.4□MnM view□432
      - 17.1.4.4.1□Key strengths□432
      - 17.1.4.4.2□Strategic choices□432
      - 17.1.4.4.3□Weaknesses & competitive threats□432
- 17.1.5□MERCK KGAA□433
  - 17.1.5.1□Business overview□433
  - 17.1.5.2□Products/Services/Solutions offered□434
  - 17.1.5.3□Recent developments□436
    - 17.1.5.3.1□Expansions□436
  - 17.1.5.4□MnM view□436
    - 17.1.5.4.1□Key strengths□436
    - 17.1.5.4.2□Strategic choices□436
    - 17.1.5.4.3□Weaknesses & competitive threats□436
- 17.1.6□AVANTOR, INC.□437
  - 17.1.6.1□Business overview□437
  - 17.1.6.2□Products/Services/Solutions offered□438
  - 17.1.6.3□Recent developments□442
    - 17.1.6.3.1□Deals□442
    - 17.1.6.3.2□Expansions□442
- 17.1.7□CRYOPORT□443
  - 17.1.7.1□Business overview□443
  - 17.1.7.2□Products/Services/Solutions offered□444
  - 17.1.7.3□Recent developments□446
    - 17.1.7.3.1□Product launches□446
    - 17.1.7.3.2□Deals□446
    - 17.1.7.3.3□Expansions□448
- ?

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.1.8 □TECAN TRADING AG □449
  - 17.1.8.1 □Business overview □449
  - 17.1.8.2 □Products/Services/Solutions offered □450
  - 17.1.8.3 □Recent developments □451
    - 17.1.8.3.1 □Product launches □451
- 17.1.9 □AZENTA US INC. □453
  - 17.1.9.1 □Business overview □453
  - 17.1.9.2 □Products/Services/Solutions offered □454
    - 17.1.9.3 □Recent developments □455
      - 17.1.9.3.1 □Product launches □455
      - 17.1.9.3.2 □Deals □456
      - 17.1.9.3.3 □Expansions □456
- 17.1.10 □GREINER AG □457
  - 17.1.10.1 □Business overview □457
  - 17.1.10.2 □Products/Services/Solutions offered □458
  - 17.1.10.3 □Recent developments □459
    - 17.1.10.3.1 □Product launches □459
    - 17.1.10.3.2 □Expansions □460
- 17.1.11 □AGILENT TECHNOLOGIES, INC. □461
  - 17.1.11.1 □Business overview □461
  - 17.1.11.2 □Products/Services/Solutions offered □462
- 17.1.12 □LABCORP □463
  - 17.1.12.1 □Business overview □463
  - 17.1.12.2 □Products/Services/Solutions offered □464
    - 17.1.12.3 □Recent developments □465
      - 17.1.12.3.1 □Deals □465
- 17.1.13 □EUROFINS SCIENTIFIC □466
  - 17.1.13.1 □Business overview □466
  - 17.1.13.2 □Products/Services/Solutions offered □467
- 17.2 □OTHER PLAYERS □468
  - 17.2.1 □HAIER BIOMEDICAL □468
  - 17.2.2 □HAMILTON COMPANY □469
  - 17.2.3 □AMSBIO □471
  - 17.2.4 □BAY BIOSCIENCES □472
  - 17.2.5 □BIOKRYO □473
  - 17.2.6 □SPT LABTECH LTD. □474
  - 17.2.7 □ASKION GMBH □475
  - 17.2.8 □CTIBIOTECH □476
  - 17.2.9 □CURELINE □477
  - 17.2.10 □FIRALIS MOLECULAR PRECISION □478
  - 17.2.11 □SOPACHEM □479
  - 17.2.12 □FROILABO □480
  - 17.2.13 □BIOIVT □481
- 18 □APPENDIX □482
  - 18.1 □DISCUSSION GUIDE □482
  - 18.2 □KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL □487
  - 18.3 □CUSTOMIZATION OPTIONS □489

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

18.4 RELATED REPORTS 490

18.5 AUTHOR DETAILS 491

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Biobanking Market by Product (Equipment, Consumables, Software), Services (Virtual), Operation (Automated), Workflow (Storage, Collection, Transport), Sample (Blood, Cell Lines, Nucleic Acids), Application, Ownership, End User - Global Forecast to 2030**

Market Report | 2025-08-23 | 492 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code\*

Country\*

Date

2026-06-09

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)